Examkin

Soru

Zorluk: ZorPharmacokinetic and Pharmacodynamic Principles

Match each clinical scenario (Left) with the underlying pharmacokinetic or pharmacodynamic principle responsible for the observed effect (Right).

  • A patient on chronic methadone maintenance receives buprenorphine, precipitating acute withdrawal symptoms.Displacement of a full agonist by a high-affinity partial agonist, reducing apparent maximal efficacy (EmaxE_{max})
  • A patient with a pheochromocytoma is given phenoxybenzamine; subsequent norepinephrine administration fails to reach typical peak pressor effects despite escalating doses.Irreversible non-competitive antagonism, reducing maximal efficacy (EmaxE_{max}) without altering agonist receptor affinity
  • A patient receiving ampicillin is co-administered probenecid to maintain sustained high serum antibiotic concentrations.Competitive inhibition of renal organic anion transporters, decreasing clearance and prolonging elimination half-life
  • A transplant recipient on cyclosporine develops acute organ rejection shortly after starting an over-the-counter herbal supplement for depression.Upregulation of hepatic cytochromes and intestinal efflux transporters, decreasing drug bioavailability and steady-state concentration

Cevap

The clinical scenarios pair with their mechanisms as follows: Buprenorphine causes withdrawal via high-affinity partial agonism. Phenoxybenzamine limits pressor effects via irreversible non-competitive antagonism. Probenecid boosts ampicillin levels via organic anion transporter (OAT) inhibition. St. John's wort causes rejection by inducing CYP3A4 and P-glycoprotein.
Each scenario accurately represents a core pharmacokinetic (PK) or pharmacodynamic (PD) concept. Buprenorphine displaces full agonists due to high affinity but exerts less effect (partial agonism). Phenoxybenzamine covalently binds receptors, decreasing the available receptor pool and capping the maximal possible response (irreversible non-competitive antagonism). Probenecid physically competes for transport sites in the kidney (pharmacokinetic OAT inhibition). St. John's wort increases the production of metabolizing enzymes and efflux pumps, clearing drugs faster (CYP3A4/P-gp induction).

Adım Adım Çözüm

1
Analyze the interaction between methadone and buprenorphine.
Buprenorphine acts as a high-affinity partial agonist, displacing the full agonist methadone from mu-opioid receptors.
Understanding differences in receptor affinity and intrinsic efficacy is necessary to explain why a partial agonist precipitates withdrawal in an opioid-dependent patient.
2
Evaluate the effect of phenoxybenzamine on norepinephrine responsiveness.
Phenoxybenzamine provides irreversible, non-competitive antagonism at alpha-adrenergic receptors.
This explains why increasing the dose of the agonist (norepinephrine) cannot overcome the blockade to restore the original maximal effect (EmaxE_{max}).
3
Assess the pharmacokinetic mechanism by which probenecid affects ampicillin levels.
Probenecid competitively inhibits renal tubular secretion via organic anion transporters (OAT).
Recognizing transport competition in the proximal tubule explains the intentional reduction in renal clearance of the antibiotic.
4
Identify the interaction between St. John's wort and cyclosporine.
St. John's wort induces CYP3A4 and P-glycoprotein, accelerating cyclosporine clearance.
This explains the subtherapeutic immunosuppressant levels leading to acute cellular rejection.

Anahtar Kavram

Pharmacodynamic receptor interactions (competitive vs. non-competitive antagonism, partial agonism) and pharmacokinetic alterations (CYP induction, OAT inhibition) dictate clinical drug responses and adverse interactions.
Bu soruyu puanla

Konular

Pharmacokinetic and Pharmacodynamic Principles

Bu konudan daha fazla soru